Navigation Links
Treatment with PEGASYS(R)/COPEGUS(TM) Provides Hope for Hepatitis C Patients Whose Infection Did Not Initially Respond to Peg-Intron(R)/Ribavirin
Date:11/2/2007

More About the REPEAT Study

Enrolling 950 patients from Europe, North America and Latin America, REPEAT (REtreatment with PEgasys in pATients Not Responding to Peg-Intron Therapy) was designed to explore whether intensified treatment with a higher fixed-dose induction of PEGASYS in combination with COPEGUS and/or longer treatment duration may increase treatment success rates in patients who didn't respond to at least twelve weeks of Peg-Intron/ribavirin combination therapy. Patients were randomized 2:1:1:2 to one of four regimens:

-- Patients in arms A (n=318) and B (n=158) received PEGASYS 360 mcg/week

for 12 weeks, followed by 180 mcg/week for a further 60 or 36 weeks,

respectively

-- Patients in arms C (n=158) and D (n=316) received PEGASYS 180 mcg/week

for 72 or 48 weeks, respectively

-- All patients received COPEGUS (1,000/1,200 mg/day) in combination with

PEGASYS

Results showed:

-- The primary endpoint was met: SVR, defined by undetectable hepatitis C

virus RNA in the blood six months after the end of treatment, was

significantly higher for arm A (16 percent) compared to arm D (nine

percent)

-- A pooled analysis of the 72-week arms vs. the 48-week arms showed that

72 weeks of treatment had the biggest impact on success of treatment,

with a doubling of SVR rate compared to 48 weeks (16 percent vs. eight

percent). A pooled analysis of the induction dose arms vs. standard

dose arms showed that treatment with higher fixed-dose induction for

this difficult-to-treat patient population did not provide significant

additional benefit

-- Response at 12 weeks was a strong predictor of successful treatment

-- Of patients whose virus was undetectable after 12 weeks of therapy,

57 percent in the 72-week arms went on to achieve treatment success

(by comparison, among patient
'/>"/>

SOURCE Roche
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Point of Care Strep Tests Speed Treatment, Lower Costs
2. Rapid HIV Testing Increases Possibility of Treatment
3. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
4. Pixantrone Combination Therapy for First-line Treatment of Aggressive Non-Hodgkins Lymphoma Results in Reduction in Severe Toxicities Including Heart Damage When Compared to Doxorubicin-based Therapy
5. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
6. BusinessWeek Article Highlights Promising Breakthrough Treatment for Advanced Coronary Artery Disease
7. TransPharma Medical Announces Positive Results of Phase I Clinical Trials for Transdermal Delivery of hPTH (1-34) for Osteoporosis Treatment
8. TMC125 Showed Significant Virologic Response at Week 24 in Treatment-Experienced HIV Patients With NNRTI Resistance in Phase 3 Trials
9. New Phase 3 Study Published in The Lancet Evaluates Efficacy and Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination Therapy in Treatment-Experienced Adults With HIV
10. BusinessWeek Article Highlights Promising Breakthrough Treatment for Advanced Coronary Artery Disease
11. Peer Reviewed Journal Article Indicates Repros Proellex Exhibits Potential for New Approach to the Treatment and Prevention of Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... , December 24, 2014 ... on Global Disposable Syringe Industry of 178 ... online business intelligence library. The ... Syringe Industry is a professional and deep ...  For overview analysis, the report introduces Disposable ...
(Date:12/24/2014)... CHENGDU, China , Dec. 23, 2014 /PRNewswire/ ... a pharmaceutical company that specializes in patented biopharmaceutical, ... active pharmaceutical ingredients (API) today announced that the ... for its Good Manufacturing Practice (GMP) certificate of ... & Drug Administration,s (CFDA). The public notice period ...
(Date:12/22/2014)... 22, 2014 NxStage Medical, Inc. (NASDAQ: ... dialysis products, announced today that the U.S. Food ... One™ to perform hemodialysis overnight while the patient ... hemodialysis. NxStage,s® System One is the first and ... this indication. Home nocturnal hemodialysis ...
Breaking Medicine Technology:World Disposable Syringe Market 2014 Report: China and Regional Analysis 2World Disposable Syringe Market 2014 Report: China and Regional Analysis 3World Disposable Syringe Market 2014 Report: China and Regional Analysis 4World Disposable Syringe Market 2014 Report: China and Regional Analysis 5TPI QLF Achieved Public Notice Status of GMP Certification 2TPI QLF Achieved Public Notice Status of GMP Certification 3NxStage Receives FDA Clearance for Home Nocturnal Hemodialysis 2NxStage Receives FDA Clearance for Home Nocturnal Hemodialysis 3
... WASHINGTON, March 7, 2011 RainDance Technologies, Inc. ... focused on the development and commercialization of a ... genetic screening panel for use on next-generation sequencing ... with the Society of Toxicology,s 50th Annual Meeting ...
... March 7, 2011 Dyadic International, Inc. (OTC Pink: ... will release financial results for the year ended December ... open to be followed by a conference call at ... The conference call may be accessed by dialing ...
Cached Medicine Technology:RainDance Technologies and Ambry Genetics Expand Collaboration to Address ADME Analysis 2RainDance Technologies and Ambry Genetics Expand Collaboration to Address ADME Analysis 3RainDance Technologies and Ambry Genetics Expand Collaboration to Address ADME Analysis 4
(Date:12/25/2014)... The microscopy market is estimated to ... $5,756.0 million by 2019. Optical microscopy is the ... microscopes product segment is expected to show the ... focus on nanotechnology, technological advancements, and increasing federal ... , Get Full Copy of Report @ ...
(Date:12/25/2014)... TX (PRWEB) December 26, 2014 The ... to 2023” focuses on the current treatment landscape, unmet ... cancer market. TS-1 is an anti-cancer drug which is ... orally and is also used for treating gastric cancer ... and otastat potassium. The drug was first approved in ...
(Date:12/25/2014)... 26, 2014 Recently, Dylan Queen, a ... excitedly released its collection of discounted prom dresses, most ... a senior spokesman of the company, the promotion is ... promotion is to expand the UK market. , The ... different colors, lengths, and styles: A-line strapless, empire strapless ...
(Date:12/25/2014)... 25, 2014 Helen Harris’ RP (Retinitis ... Hills, California after an 8 year battle with breast ... Eve evening in her home in Woodland Hills California ... cancer. , As the founder and ... she pioneered and championed many of today's greatest breakthroughs ...
(Date:12/25/2014)... Dec. 25, 2014 (HealthDay News) -- The risk of ... holidays, so you need to be extra cautious, an ... we see a significant increase in patients coming in ... the Suffolk County Volunteer Firefighters Burn Center of Stony ... should be full of joy, but if not careful, ...
Breaking Medicine News(10 mins):Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 2Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 3Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 4Health News:TS-1 Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 2Health News:TS-1 Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 3Health News:Dylan Queen: Cheap Prom Dresses for the UK Market 2Health News:RP International founder, Helen Harris Dies on Christmas Eve Just Hours Before Her Holiday Television Broadcast to Raise Funds to Cure Blindness was Broadcasted Nationally 2Health News:RP International founder, Helen Harris Dies on Christmas Eve Just Hours Before Her Holiday Television Broadcast to Raise Funds to Cure Blindness was Broadcasted Nationally 3Health News:RP International founder, Helen Harris Dies on Christmas Eve Just Hours Before Her Holiday Television Broadcast to Raise Funds to Cure Blindness was Broadcasted Nationally 4Health News:Don't Let Burns Mar Your Holidays 2
... Group, Inc.,(NYSE Alternext US: QGP) ( www.QuantumMD.com ) announced ... debut at the 2009 Pri-Med,South Conference and Expo alongside ... Quantum believes PWeR is the next generation in healthcare ... Obama is calling for within,the industry. Pete Martinez, ...
... . , This minimally invasive procedure, pioneering ... surgeons at the University Hospital of Navarra, which brings ... , The results obtained in patients were recently published ... Annals of Surgery . It is the highest ...
... research plays a significant role in African-Americans, lack ... study by researchers at Children,s Hospital of Pittsburgh ... School of Public Health. , African-Americans are ... published in the February issue of Archives ...
... Iowa, Feb. 3 Bio-Research Products,announced today that it ... enzyme Glutathione Reductase (GR). Dr. Bryce Cunningham, President and,Chief ... first,commercial version of the enzyme as a readily soluble ... Glutathione Reductase is part of test kits ...
... New hidden-camera footage from Tucson, AZ, implicates a ... scandal. In the video, UCLA student Lila ... Planned Parenthood clinic where Rose tells the nurse that ... 27-year-old boyfriend. The nurse disregards the age difference and ...
... The Center for Association Resources, an,association management and ... is pleased to announce the launch of an,innovative e-learning ... in the,healthcare industry. The implementation of the service will ... as deliver educational segments via,CCTV. , ...
Cached Medicine News:Health News:PWeR(TM) Introduced at Regional Healthcare Conference 2Health News:PWeR(TM) Introduced at Regional Healthcare Conference 3Health News:PWeR(TM) Introduced at Regional Healthcare Conference 4Health News:Surgical technique in Spain enables extirpation of benign tumors of the pancreas 2Health News:Children's Hospital study finds African-Americans more distrusting of research than whites 2Health News:Children's Hospital study finds African-Americans more distrusting of research than whites 3Health News:New Undercover Video Shows Tucson Planned Parenthood Hiding Rape of 15-Year-Old Girl 2Health News:Center for Association Resources Launches E-Learning Service 2
... The table top design takes into account ... creates a flexible working environment for the ... alphamaxx can be matched exactly to your ... slide capability creates superior access for image ...
... is the Market leader in soft tissue ... DePuy Mitek has developed the latest evolution ... shoulder repair. ORTHOCORD Suture is as strong ... market. Most importantly, ORTHOCORD Suture handles like ...
... Now you can ... tactile sensitivity of the ... Free surgical gloves on ... Free gloves provide the ...
... Siegel MAST Intraoperative Leg Positioner frees the OR ... need for 2nd assistants to hold the leg, ... the procedure instead of leg positioning. The Siegel ... the leg in any position required for knee ...
Medicine Products: